Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Precise Cancer Anti-acid Therapy Monitoring Using pH-Sensitive MnO<sub>2</sub>@BSA Nanoparticles by Magnetic Resonance Imaging.

ACS applied materials & interfaces·2021

Same author

Effects of histone H4 hyperacetylation on inhibiting MMP2 and MMP9 in human amniotic epithelial cells and in premature rupture of fetal membranes.

Experimental and therapeutic medicine·2021

Same author

Regulatory roles and mechanisms of alternative RNA splicing in adipogenesis and human metabolic health.

Cell & bioscience·2021

Same author

Diluted-CdS Quantum Dot-Assisted SnO<sub>2</sub> Electron Transport Layer with Excellent Conductivity and Suitable Band Alignment for High-Performance Planar Perovskite Solar Cells.

ACS applied materials & interfaces·2021

Same author

A microporous surface containing Si<sub>3</sub>N<sub>4</sub>/Ta microparticles of PEKK exhibits both antibacterial and osteogenic activity for inducing cellular response and improving osseointegration.

Bioactive materials·2021

Same author

Clinical importance of ADC in the prediction of <sup>125</sup>I in the treatment for gliomas.

Journal of Cancer·2021

Search research articles

Related Experiment Video

Updated: Sep 16, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

IL-18 revives dysfunctional CAR-T cells.

Yan-Ruide Li¹, Yichen Zhu¹, Lili Yang²

¹Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.

Trends in Cancer

|July 8, 2025

Summary

Interleukin-18-armored chimeric antigen receptor (CAR)-engineered T (18.CAR-T) cells show improved effectiveness against lymphoma in patients resistant to standard CAR-T therapy. Further research aims to understand their mechanisms and reduce side effects for advanced CAR-T treatments.

Keywords:

CAR-T dysfunction cancer therapy chimeric antigen receptor (CAR)interleukin-18 (IL-18)superior antitumor efficacy

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

Related Experiment Videos

Last Updated: Sep 16, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

Area of Science:

Immunotherapy
Oncology
Cellular Therapy

Background:

Chimeric antigen receptor (CAR)-engineered T-cell therapy is a promising cancer treatment.
Conventional CAR-T therapy faces challenges with efficacy in certain patient populations, particularly those with refractory lymphoma.
Interleukin-18 (IL-18) has immunomodulatory properties that could enhance CAR-T cell function.

Purpose of the Study:

To investigate the enhanced antitumor efficacy of IL-18-armored CAR-T (18.CAR-T) cells in lymphoma.
To elucidate the underlying mechanisms responsible for the improved potency of 18.CAR-T cells.
To identify strategies for mitigating potential toxicities associated with next-generation CAR-T therapies.

Main Methods:

Development and characterization of IL-18-armored CAR-T cells.
In vitro and in vivo studies evaluating the antitumor activity against lymphoma models.
Analysis of immune cell function, cytokine profiles, and potential adverse effects.

Main Results:

18.CAR-T cells demonstrated superior efficacy compared to conventional CAR-T cells in preclinical lymphoma models.
Specific mechanisms contributing to enhanced T-cell persistence and tumor cell killing were identified.
Preliminary data suggests a manageable toxicity profile, warranting further investigation.

Conclusions:

IL-18-armored CAR-T cells represent a promising advancement in CAR-T therapy for refractory lymphoma.
Understanding the mechanisms of action and toxicity is crucial for clinical translation.
This approach holds potential for developing next-generation CAR-T therapies with improved clinical outcomes.